Gendius partners with the University of Nottingham to develop AI risk prediction technology
The project was awarded £250,000 of funding from Innovate UK.
Digital health innovator, Gendius, has partnered with experts at the University of Nottingham’s Digital Research Service to develop highly accurate risk prediction technology for diabetes complications, such as chronic kidney disease (CKD) and cardiovascular disease (CVD). The artificial intelligence algorithms developed through the partnership will be used to optimise Gendius’ world-leading diabetes risk management platform, Intellin®.
The project, which officially started in July 2021, is being led by Dr Philip Quinlan and Dr Grazziela Figueredo from the Digital Research Service at the University, and was made possible thanks to £250k of funding from Innovate UK.
Dr Grazziela Figueredo comments, “This is an exciting opportunity to work with an interdisciplinary team to research and develop responsible AI tools that will help GPs promote better care for diabetes patients. This project will help clinicians and patients to better understand diabetes-associated disease progression and how individual behavioural changes might impact it.”
Manchester-based Gendius is one of the UK’s leading MedTech startups, and has developed advanced diabetes management solutions powered by its proprietary AI-driven technology. Gendius uses a clinically validated logic engine, its Intellin® platform, to actively monitor patients’ diabetes management.
Intellin® uses individual clinical histories to highlight users’ risk of developing diabetes-related complications, not only enabling people with diabetes to take more control over their condition, but also allowing clinicians to provide more targeted advice and management strategies.
Rory Cameron, Chief Executive Officer and Co-founder of Gendius, says, “We have been working with the team at the University of Nottingham for several years and this award enables us to move forward in our algorithm development. The team have a unique blend of data science, behaviour change and developer expertise that will make a considerable impact to our Intellin® platform.
He continues, “Diabetes is the leading cause of kidney failure, lower limb amputation, blindness and considerably increases your risk of a cardiovascular event and this partnership will help us in our journey to understand and prevent the complications of chronic diseases such as diabetes.”
Identifying and treating diabetes complications early has been highlighted as a key way of improving outcomes for people with diabetes. Diabetes is the most common cause of end-stage kidney failure in the UK, and it doubles the risk of cardiovascular disease, including heart attack, heart failure, angina, and stroke. It is estimated that treatment of diabetes and diabetes complications accounts for 9% of the total NHS budget, and that 10% of NHS hospital beds are occupied by people with diabetes.
